Anti-HER2 therapyHER-2/neubreast cancerelderlyTargeting anti-HER-2 therapy, trastuzumab, Lapatinib, T-DM1, and Pertuzumab is a standard therapy for HER-2-overexpressing breast cancer. But there are less data available related to anti-HER-2 therapy in elderly patients because they have been ...
Metastatic HER2 + breast cancer is an expanding area of drug development and research, with three new drugs approved in 2020 alone. While first-line therapy is well-established for metastatic HER2 + breast cancer, the standard of care for second-line therapy will likely be changing soo...
Genomic studies have identified distinct breast cancer subtypes with differences in survival and response to therapy, including luminal A, luminal B, basal-like, HER2+ and Claudin-low subtypes1,2. HER2 overexpression leads to aggressive cancer phenotype and poor patient survival. Trastuzumab, a humani...
We report here the annual hazards of recurrence based on hormone receptor (HR) status among patients with HER2+ early BC treated with chemotherapy +/− endocrine therapy but not with anti-HER2 therapy. Methods Study design and participants Our analyses are based on data from the placebo arm ...
Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti-HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti-HER2...
Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti-HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti-HER2...
The sole use of single modality data often fails to capture the complex heterogeneity among patients, including the variability in resistance to anti-HER2 therapy and outcomes of combined treatment regimens, for the treatment of HER2-positive gastric can
1. Extended anti-HER2 therapy in early breast cancer: longer beats shorter? [J] . Refae Sadal, Pistilli Barbara, Delaloge Suzette Current Opinion in Oncology . 2016,第6期 机译:早期乳腺癌中延长抗HER2治疗的时间:拍子越短越短? 2. Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Meta...
Severe PTEN deficiency is also associated with advanced tumor stage and therapeutic resistance, such as the resistance to trastuzumab, an anti-HER2 therapy... S Zhang,D Yu 被引量: 340发表: 2010年 HER2-positive gastric cancer the future prospects of other anti-HER2 drugs, including lapatinib, ...
"With the advent of anti-HER2 therapy inmetastatic colorectal cancer, the key question for HER2-amplified RAS/BRAF wild-type tumors is who should be preferentially treated with therapy directed against HER2 vis-à-vis EGFR," said lead author and S1613 study chair Kanwal Raghav, MD, MBBS, an...